No description available.

La transglutaminase tissulaire est une enzyme dépendante du calcium qui catalyse la formation de liens isopeptidiques, entre les chaînes latérales de résidus glutamine et lysine, permettant, par le fait même, la réticulation des protéines dans les systèmes biologiques. Elle joue un rôle, entre autres, dans l’endocytose, la régulation du développement des cellules, et même dans l’apoptose. Néanmoins, une dérégulation de l’activité biologique de cette enzyme peut entrainer différentes pathologies, comme la formation de cataractes, de plaques amyloïdes dans la maladie d’Alzheimer, ou encore peut mener au développement de la maladie céliaque. C’est pourquoi une meilleure connaissance du mécanisme d’action de cette enzyme et la possibilité de réguler son action à l’aide de substrats ou d’inhibiteurs sont nécessaires. Dans cette optique, une méthode d’expression et de purification de la transglutaminase humaine a été développée, permettant de travailler directement avec la cible pharmacologique désirée. De plus, une étude du mode d’inhibition et de liaison d’une classe d’inhibiteurs réversibles précédemment découverte dans le groupe, soit la famille des trans-cinnamoyles, a permis d’identifier que la puissance de ces molécules est influencée par la présence du calcium et qu’une inhibition dépendante du temps est observée, en lien avec un potentiel équilibre conformationnel lent de la transglutaminase. D’un autre côté, la susceptibilité à une attaque nucléophile par des thiols de cette classe de molécule rend leur potentiel pharmacologique grandement diminué, et c’est pourquoi une nouvelle famille de molécules a été identifiée, basée sur un squelette ynone, avec une valeur d’IC50 très prometteuse de 2,6 μM, en faisant un des meilleurs inhibiteurs réversibles de la transglutaminase développés à ce jour. Finalement, une stratégie de photomarquage jumelée à une analyse de spectrométrie de masse en tandem a été développée pour la découverte du site de liaison du substrat dérivé de la lysine, dans le but de mieux comprendre le mécanisme complexe de cette enzyme. / Tissue transglutaminase is a calcium-dependent enzyme that catalyzes the formation of isopeptide bonds between the side chains of glutamine and lysine residues, thereby resulting in the crosslinking of proteins in biological systems. It plays a role, among others, in endocytosis, the regulation of cell growth, and even in apoptosis. However, a deregulation of the biological activity of this enzyme can result in various pathologies, such as cataract formation, amyloid plaque formation in Alzheimer’s disease, or the development of celiac disease. Therefore, a better understanding of the mechanism of action of this enzyme and the ability to regulate its action using inhibitors or substrates is necessary. In this context, a method of expression and purification of human transglutaminase has been developed, allowing one to work directly with the desired pharmacological target. In addition, a study of the mode of inhibition and binding mode of a reversible inhibitor class previously discovered in the group, the family of trans-cinnamoyl derivatives, revealed that the potency of these molecules is influenced by the presence of calcium and a time-dependent inhibition is observed, related to a putative slow conformational equilibrium of transglutaminase. On the other hand, the susceptibility of this class of molecules to nucleophilic attack by thiols greatly diminishes their pharmacological potential, and that is why a new family of molecules has been identified, based on a ynone skeleton, with a very promising IC50 value of 2.6 μM, making this molecule one of the best transglutaminase reversible inhibitors developed to date. Finally, a photolabelling strategy combined with a tandem mass spectrometry analysis has been developed for the discovery of the binding site of the lysine derivative substrate, in order to better understand the complex mechanism of this enzyme.

Die Xanthin-Dehydrogenase aus Rhodobacter capsulatus ist ein cytoplasmatisches Enzym, welches ein (αβ)₂ Heterotetramer mit einer Größe von 275 kDa bildet. Die drei Kofaktoren (Moco, 2[2Fe2S], FAD) sind auf zwei unterschiedlichen Polypeptidketten gebunden. So sind die beiden spektroskopisch unterscheidbaren Eisen-Schwefel-Zentren und das FAD in der XdhA-Untereinheit und der Moco in der XdhB-Untereinheit gebunden. Im ersten Teil dieser Arbeit sollte untersucht werden, warum die R. capsulatus XDH ein Dimer bildet und ob ein intramolekularer Elektronentransfer existiert. Dafür wurde eine chimäre XDH-Variante [(α)₂(β₁wt/β₂E730A)] erzeugt, welche eine aktive und eine inaktive XdhB-Untereinheit trägt. Mit Hilfe von Reduktionsspektren sowie mit der Bestimmung der kinetischen Parameter für die Substrate Xanthin und NAD+ konnte gezeigt werden, dass die chimäre XDH-Variante katalytisch halb so aktiv war, wie der auf gleiche Weise gereinigte XDH-Wildtyp. Dies verdeutlicht, dass die noch aktive Untereinheit der Chimären selbstständig und unabhängig Substrat binden und hydroxylieren kann und ein intramolekularer Elektronentransfer zwischen den beiden XdhB-Untereinheiten nicht stattfindet. Ein weiteres Ziel war die funktionelle Charakterisierung der Mus musculus AOX1 sowie der humanen AOX1 hinsichtlich ihrer Substratspezifitäten und ihrer biophysikalischen Eigenschaften sowie der Charakterisierung der konservierten Aminosäuren im aktiven Zentrum der mAOX1. Da bislang noch kein heterologes Expressionssystem für ein aktives und stabiles rekombinantes AO-Protein existierte, wurde ein E. coli Expressionssystem mit der gleichzeitigen Expression der entsprechenden Mocosulfurase für mAOX1 und hAOX1 in dieser Arbeit etabliert. Mit Hilfe dieser Koexpression konnte die Aktivität der rekombinanten mAOX1 um 50 % gesteigert werden, wenn gleich auch der sulfurierte Moco-Anteil nur 20 % betrug. Um die konservierten Aminosäuren im aktiven Zentrum hinsichtlich ihrer Funktion der Substratbindung zu charakterisieren, wurden folgende Varianten erzeugt: V806E, M884R, V806/M884R sowie E1265Q. Mit Hilfe von kinetischen Substratuntersuchungen konnte gezeigt werden, dass die beiden Aminosäuren Val806 und Met884 für die Erkennung und die Stabilisierung von Aldehyden und N-Heterozyklen essentiell sind. Ein Austausch dieser beiden gegen Glutamat bzw. Arginin (wie bei R. capsulatus XDH) zeigte jedoch keine Xanthin- oder Hypoxanthinumsetzung. Für das Glu1265 wurde ebenfalls die Rolle als die Katalyse initiierende Aminosäure belegt. / The main task of this work was to analyse the function of R. capsualtus Xanthine Dehydrogenase (R.c. XDH; EC 1.17.1.4) as well as to characterize the structure and function of mouse Aldehyde Oxidase (mAOX1; EC 1.2.3.1). Both enzymes are complex metallo-flavoproteins that contain two nonidentical [2Fe2S] clusters, FAD and the molybdenum cofactor (Moco) as catalytically acting units. AO and XDH are members of the xanthine oxidase family characterized by an equatorial sulfur ligand at the Moco site essential for enzyme activity. To solve the question why R.capsualtus XDH forms a dimer a chimeric variant of bacterial XDH was produced and expressed in E.coli. By means of the (alphabeta)(2) XDH heterotetramer variant, that should include only one active Moco-center, it should be analysed if the two subunits act independent without cooperativity. AO is characterized by broad substrate specificity and this makes it an important enzyme for the metabolism of drugs and xenobiotica. The biochemical and physiological function of AO is still largely obscure and only limited information is available on the physiological substrates of AO or the role of the enzyme in mammalia. The substrate specificity of the recombinant AO should be determined by different purines and aldehydes. In order to determine the function of conserved amino acides, site directed mutagenesis of amino acides at the active site (Val806Glu, Met884Arg, Glu1265Gln) were introduced and enzyme activity was determined. Bacterial XDH is highly homologous to the homodimeric mammalian xanthine oxidoreductase - in the amino acid sequence and the secondary and tertiary protein structure as well as the reaction mechanism as described by Leimkühler et al. (2004). Therefore, in the second part of this work, bacterial XDH will be used as a benchmark for mAOX1 during determination of enzyme acitivities using different purines and aldehydes as substrates. A single monogentic deficit of AO has not been described for humans yet. To identify the biochemical function and to characterize the enzyme in detail a system for a heterologous expression of functionally active hAOX1 in E.coli should be established too.

In der vorliegenden Arbeit wurde der ATP-gekoppelte uphill Elektronentransfer von reduziertem RACo auf Kobalt(II)-CoFeSP untersucht. Dazu wurden zunächst die Bedingungen der rekombinanten Genexpression in Escherichia coli und die Reinigungsstrategie der Proteine verbessert, um einen Cofaktorgehalt beider Proteine von annähernd 100 % zu erreichen. Anschließend wurden die Reaktionsbedingungen des Elektronentransfers optimiert, um eine tiefergehende Analyse zu ermöglichen. Die Ergebnisse dieser Arbeit deuten darauf hin, dass durch die Bindung von ATP ein bidirektionaler Elektronentransfer induziert wird. Der Elektronentransfer konnte mit nicht-hydrolysierbaren ATP-Analoga und mit ADP induziert werden. Weder für die nicht-hydrolysierbaren ATP-Analoga noch für ADP konnten anschließend Hydrolyseprodukte nachgewiesen werden. Zusätzlich konnte für die limitierende Rate der ATP-Hydrolyse ein mehr als 100-fach kleinerer Wert bestimmt werden als für den Elektronentransfer. Beide Ergebnisse zeigen, dass der Elektronentransfer unabhängig von der ATP-Hydrolyse ist. Kobalt(I)-CoFeSP kann jedoch auch ein Elektron auf oxidiertes RACo übertragen, was auf einen bidirektionalen Elektronentransfer hindeutet. Diese These wurde mit der Beobachtung untermauert, dass sich durch Zugabe von ADP und der Erhöhung der ADP-Konzentration die Anzahl der transferierten Elektronen pro CoFeSP zunimmt und sich somit die Lage des entstehenden Gleichgewichts verschieben lässt. Auf dieser Datengrundlage konnten drei mögliche Modelle für den Reaktionsmechanismus erstellt werden, von welchen ein Modell als am wahrscheinlichsten erscheint. In diesem Reaktionsmechanismus gleichen sich die Redox-Potentiale beider Redox-Zentren durch die ATP-Bindung an. Dies ermöglicht den Elektronentransfer vom [2Fe2S]-Cluster von RACo auf das Kobalt-Ion des Cobalamins. Die Rückreaktion wird durch eine erneute Reduktion des [2Fe2S]-Clusters verhindert und durch die anschließende ATP-Hydrolyse dissoziiert der Komplex. / In the present work, ATP-coupled uphill electron transfer from reduced RACo to cobalt(II)-CoFeSP was investigated. For this purpose, the conditions of recombinant gene expression in Escherichia coli and the purification strategy of the proteins were improved to achieve a cofactor content of both proteins close to 100%. Subsequently, the electron transfer reaction conditions were optimized to enable a more in-depth analysis. The results of this work indicate that a bidirectional electron transfer is induced by the binding of ATP. Electron transfer could be induced with non-hydrolysable ATP analogues and with ADP. Neither for the nonhydrolyzable ATP analogues nor for ADP hydrolysis products could subsequently be detected. In addition, a value more than 100-fold smaller could be determined for the limiting rate of ATP hydrolysis than for electron transfer. Both results indicate that electron transfer is independent of ATP hydrolysis. However, cobalt(I)-CoFeSP can also transfer an electron to oxidized RACo, suggesting bidirectional electron transfer. This hypothesis was supported with the observation that adding ADP and increasing the ADP concentration increases the number of transferred electrons per CoFeSP by shifting the position of the emerging equilibrium. Based on these data, three possible models for the reaction mechanism are suggested, of which one model appears to be the most plausible. In this reaction mechanism, the redox potentials of both redox centers equalize due to ATP binding. This allows electron transfer from the [2Fe2S] cluster of RACo to the cobalt ion of cobalamin. The back reaction is prevented by a further reduction of the [2Fe2S] cluster, and subsequent ATP hydrolysis dissociates the complex

A doença de Chagas, causada pelo protozoário flagelado Trypanosoma cruzi, é uma doença tropical que enseja morte/morbidade de milhões de pessoas na América Latina. Por processos migratórios, vem-se estendendo ao sul dos Estados Unidos, Canadá, Europa, Austrália e Japão. Essa doença tem sido considerada super-negligenciada pela indústria farmacêutica, já que os dois fármacos disponíveis para o seu tratamento foram introduzidos há mais de quarenta anos e apresentam baixa eficácia com vários efeitos colaterais severos. Mais recentemente, a Organização Mundial da Saúde considerou a doença de Chagas, dentre outras, como a doença da pobreza! Com esse cenário completamente desfavorável aos portadores da doença, é necessária a descoberta, desenvolvimento e introdução de novos fármacos para o tratamento eficiente e seguro da doença de Chagas. <br />Dentro desse contexto, este trabalho representa uma importante contribuição para o entendimento das razões moleculares da ação farmacológica de substâncias químicas bioativas de interesse à farmacoterapia da doença de Chagas. Ao nível molecular, a enzima pertencente à via de síntese de novo de nucleotídeos de pirimidinas, diidroorotato desidrogenase do Trypanosoma cruzi (TcDHODH), é um alvo promissor para a descoberta e desenvolvimento de candidatos a fármacos de interesse para o tratamento da doença de Chagas. <br />Os conceitos e ferramentas da química medicinal computacional, tais como os ensaios virtuais in silico, foram usados para a identificação de inibidores da TcDHODH. Vinte e seis substâncias inéditas como inibidores da TcDHODH foram adquiridos comercialmente e avaliados experimentalmente através da Calorimetria de Titulação Isotérmica (ITC) para a determinação do mecanismo de inibição e da constante cinética de afinidade (Kiapp). <br />Na etapa de docagem molecular, o objetivo era identificar moléculas que apresentassem uma boa afinidade pelo sítio ativo da enzima TcDHODH. A primeira série de ligantes selecionados dos métodos in silico, apresentou inibição enzimática na concentração de micromolar com eficiência média de ligante de 0,50 kcal mol-1 átomo-1. Devido à baixa massa molecular (aproximadamente 200 kDa) e a alta eficiência de ligante, essa série foi considerada como constituída de excelentes substâncias com elevado poder de reconhecimento biomolecular. Por isso, foram caracterizadas como substâncias passíveis de otimização no processo do-ligante-para-substância matriz. <br />As enzimas TcDHODH e DHODH de Leishmania major (LmDHODH) têm sítios ativos com elevado grau de similaridade. Portanto, usando a enzima LmDHODH como padrão de substituição da TcDHODH é possível fazer a descrição do modo de interação do co-complexo TcDHODH-inibidor. O modo de ação descrito através da resolução da estrutura cristalográfica de raios-X, além de validar ortogonalmente os resultados cinéticos obtidos por ITC - que identificou as substâncias como inibidores competitivos (por interação direta no sítio ativo da enzima TcDHODH), geraram hipóteses farmacofóricas para a busca de novas moléculas (chamadas de segunda geração), agora com padrão superior de reconhecimento molecular do sítio da TcDHODH. Para validar complementarmente a hipótese, foi demonstrado que os inibidores da TcDHODH inibem, similarmente, a LmDHODH. <br />Uma análise cuidadosa da estrutura tridimensional da enzima TcDHODH, demostrou a possibilidade de ocupação do sítio S2 que se estende além da região do sítio catalítico S1, permitindo assim o aumento da afinidade biomolecular com os inibidores. Além disso, o sítio S2 não é encontrado na estrutura da proteína de humanos (HsDHODH), podendo ser uma região passível de seletividade frente à enzima TcDHODH. <br />O emprego adequado dessa hipótese resultou na otimização dos ligantes identificados previamente para substâncias mais potentes que inibiram a enzima de forma competitiva em relação ao substrato diidroorotato (DHO) em valores Kiapp de 121 &plusmn; 14 nM e 190 &plusmn; 10 nM. <br />A técnica de ITC foi fundamental no processo de descoberta de inibidores enzimáticos, pois se mostrou extremamente susceptível à determinação da interação intermolecular enzima-inibidor, permitindo acompanhar a cinética da reação e obter os valores da constante de afinidade de maneira precisa e acurada. Com isso, a taxa de acerto obtida nesta tese foi de 46%, considerando-se apenas as substâncias com valores de Ki app < 100 &micro;M. Esse é um número favoravelmente apreciável, já que na literatura ele gira em torno de 1-10% quando o planejamento in silico é realizado, quando comparado às taxas de acerto dos métodos de ensaio em larga escala (HTS), entre 0-2 %, os resultados alcançados neste trabalho são ainda mais significativos. <br />Além disso, as substâncias químicas selecionadas através da integração de métodos in silico e biocalorimétricos apresentam elevado grau de complexidade no processo biomolecular de interação enzima-ligante, que permite classificá-las para as fases seguintes da gênese planejada de fármacos. / American trypanosomiasis or Chagas disease, caused by the haemoflagellate Trypanosoma cruzi, is a tropical disease that affects millions of people in Latin America. Epidemiology of Chagas disease in non-endemic countries is attained by immigration as the disease also affects people in the United States, Canada, Europe, Australia and Japan. However, the United States are not to be written off as an area of nonendemicity for Chagas disease like Europe or Asia because the southern states have enzootic T. cruzi transmission that involves triatomine species and hosts such as raccoons, opossums, and domestic dogs. Even though, this disease has been considered as a super-neglected from the big Pharma Industry viewpoint since the only available drugs for its treatment were introduced in the market more than forty years ago and worsen is that they have low efficacy and cause various severe side effects. <br />Although the current clinical scenario is of course discouraging and is far from being even a soothing treatment for those who suffer from the disease, it prompt ones to set efforts towards the need of discovering and developing new efficacious and safe drugs to treat Chagas disease. <br />Our research group covers the concept of enzymes acting as targets for the action of drugs. Once T. cruzi has many druggable targets, the dihydroorotate dehydrogenase enzyme (TcDHODH) that belongs to the de novo pyrimidine nucleotide synthetic pathway has been chosen for the search of new inhibitors that may be of use in the treatment of Chagas disease. To accomplish with this and considering that inhibitors are molecules that decrease enzyme activity leading to parasite death, we used the concepts and tools of modern computational medicinal chemistry such as in silico screening of small molecules that bind to the active site of the TcDHODH. <br />After a thoroughly program of virtually screening thousands of compounds, 26 were purchased from commercially available sources and experimentally assayed against the TcDHODH using Isothermal Titration Calorimetry (ITC) in order to determine the mechanism of inhibition and the kinetic affinity constant (Kiapp). <br />The first series of inhibitors selected from our in silico strategy were evaluated by ITC to yield compounds that inhibited the TcDHODH in the micromolar concentration range with an average of 0.50 kcal mol-1 atom-1 ligand efficiency (LE). Because the assayed compounds have low molecular weight (ca. 200 kDa) and high LE, which bring them to the specific bimolecular pattern recognition all of them were considered good inhibitors capable of being selected to enter the hit-to-lead optimization process. <br />The detailed description of the ligand-enzyme mode of binding (MOB) is thoroughly accomplished by solving the X ray crystal structure of the surrogate Leishmania major DHODH enzyme (LmDHODH), which has a high degree of similarity with the enzyme TcDHODH. The MOB credited to be in the active site of the TcDHODH orthogonally validated the ITC kinetic experimental data obtained for all ligands as competitive inhibitors that interact at the active site of the TcDHODH and helped to generate pharmacophoric hypotheses for the search of new second generation molecules acting against the enzyme TcDHODH.  Analyzing the 3D structure of the TcDHODH along with its surrogate LmDHODH, we envisaged the possibility of compounds to extend their side chain beyond the region of the catalytic site (called S1), and interacting in a region called S2, so to increase binding affinity. Moreover, the TcDHODH S2 site that is not found in the 3D protein structure of humans (HsDHODH) is likely to offer new insights for the search of inhibitors whose binding to this S2 site can pave the roads towards the needed structural basis for selective inhibition of TcDHODH. <br />The most potent compounds inhibited the enzyme competitively with respect to the substrate dihydroorotate (DHO) at Kiapp values of 121 &plusmn; 14 nM and 190 &plusmn; 10 nM, which constitutes high affinity TcDHODH inhibitors. The ITC technique was pivotal to this process of enzyme inhibitors discovery, because it proved to be extremely sensitive thus allowing to monitor the kinetics of the reaction and to obtain precise and accurate values of affinity constants. <br />The hit rate obtained in this work, considering only those compounds with Kiapp < 100 &micro;M, was 46%. This is a really high number, since literature values range from 1 to 10% when the planning new inhibitors via in silico methods when compared to the success rates obtained by the methods of testing on large scales (HTS), 0-2 %, the results achieved in this work are even more significant. Moreover, the compounds selected through the integration of in silico and calorimetric methods showed a high degree of complexity in the process of bimolecular enzyme-ligand recognition, which allows to pass them to the next phase of the drug design process.

A doença de Chagas, causada pelo protozoário flagelado Trypanosoma cruzi, é uma doença tropical que enseja morte/morbidade de milhões de pessoas na América Latina. Por processos migratórios, vem-se estendendo ao sul dos Estados Unidos, Canadá, Europa, Austrália e Japão. Essa doença tem sido considerada super-negligenciada pela indústria farmacêutica, já que os dois fármacos disponíveis para o seu tratamento foram introduzidos há mais de quarenta anos e apresentam baixa eficácia com vários efeitos colaterais severos. Mais recentemente, a Organização Mundial da Saúde considerou a doença de Chagas, dentre outras, como a doença da pobreza! Com esse cenário completamente desfavorável aos portadores da doença, é necessária a descoberta, desenvolvimento e introdução de novos fármacos para o tratamento eficiente e seguro da doença de Chagas. <br />Dentro desse contexto, este trabalho representa uma importante contribuição para o entendimento das razões moleculares da ação farmacológica de substâncias químicas bioativas de interesse à farmacoterapia da doença de Chagas. Ao nível molecular, a enzima pertencente à via de síntese de novo de nucleotídeos de pirimidinas, diidroorotato desidrogenase do Trypanosoma cruzi (TcDHODH), é um alvo promissor para a descoberta e desenvolvimento de candidatos a fármacos de interesse para o tratamento da doença de Chagas. <br />Os conceitos e ferramentas da química medicinal computacional, tais como os ensaios virtuais in silico, foram usados para a identificação de inibidores da TcDHODH. Vinte e seis substâncias inéditas como inibidores da TcDHODH foram adquiridos comercialmente e avaliados experimentalmente através da Calorimetria de Titulação Isotérmica (ITC) para a determinação do mecanismo de inibição e da constante cinética de afinidade (Kiapp). <br />Na etapa de docagem molecular, o objetivo era identificar moléculas que apresentassem uma boa afinidade pelo sítio ativo da enzima TcDHODH. A primeira série de ligantes selecionados dos métodos in silico, apresentou inibição enzimática na concentração de micromolar com eficiência média de ligante de 0,50 kcal mol-1 átomo-1. Devido à baixa massa molecular (aproximadamente 200 kDa) e a alta eficiência de ligante, essa série foi considerada como constituída de excelentes substâncias com elevado poder de reconhecimento biomolecular. Por isso, foram caracterizadas como substâncias passíveis de otimização no processo do-ligante-para-substância matriz. <br />As enzimas TcDHODH e DHODH de Leishmania major (LmDHODH) têm sítios ativos com elevado grau de similaridade. Portanto, usando a enzima LmDHODH como padrão de substituição da TcDHODH é possível fazer a descrição do modo de interação do co-complexo TcDHODH-inibidor. O modo de ação descrito através da resolução da estrutura cristalográfica de raios-X, além de validar ortogonalmente os resultados cinéticos obtidos por ITC - que identificou as substâncias como inibidores competitivos (por interação direta no sítio ativo da enzima TcDHODH), geraram hipóteses farmacofóricas para a busca de novas moléculas (chamadas de segunda geração), agora com padrão superior de reconhecimento molecular do sítio da TcDHODH. Para validar complementarmente a hipótese, foi demonstrado que os inibidores da TcDHODH inibem, similarmente, a LmDHODH. <br />Uma análise cuidadosa da estrutura tridimensional da enzima TcDHODH, demostrou a possibilidade de ocupação do sítio S2 que se estende além da região do sítio catalítico S1, permitindo assim o aumento da afinidade biomolecular com os inibidores. Além disso, o sítio S2 não é encontrado na estrutura da proteína de humanos (HsDHODH), podendo ser uma região passível de seletividade frente à enzima TcDHODH. <br />O emprego adequado dessa hipótese resultou na otimização dos ligantes identificados previamente para substâncias mais potentes que inibiram a enzima de forma competitiva em relação ao substrato diidroorotato (DHO) em valores Kiapp de 121 &plusmn; 14 nM e 190 &plusmn; 10 nM. <br />A técnica de ITC foi fundamental no processo de descoberta de inibidores enzimáticos, pois se mostrou extremamente susceptível à determinação da interação intermolecular enzima-inibidor, permitindo acompanhar a cinética da reação e obter os valores da constante de afinidade de maneira precisa e acurada. Com isso, a taxa de acerto obtida nesta tese foi de 46%, considerando-se apenas as substâncias com valores de Ki app < 100 &micro;M. Esse é um número favoravelmente apreciável, já que na literatura ele gira em torno de 1-10% quando o planejamento in silico é realizado, quando comparado às taxas de acerto dos métodos de ensaio em larga escala (HTS), entre 0-2 %, os resultados alcançados neste trabalho são ainda mais significativos. <br />Além disso, as substâncias químicas selecionadas através da integração de métodos in silico e biocalorimétricos apresentam elevado grau de complexidade no processo biomolecular de interação enzima-ligante, que permite classificá-las para as fases seguintes da gênese planejada de fármacos. / American trypanosomiasis or Chagas disease, caused by the haemoflagellate Trypanosoma cruzi, is a tropical disease that affects millions of people in Latin America. Epidemiology of Chagas disease in non-endemic countries is attained by immigration as the disease also affects people in the United States, Canada, Europe, Australia and Japan. However, the United States are not to be written off as an area of nonendemicity for Chagas disease like Europe or Asia because the southern states have enzootic T. cruzi transmission that involves triatomine species and hosts such as raccoons, opossums, and domestic dogs. Even though, this disease has been considered as a super-neglected from the big Pharma Industry viewpoint since the only available drugs for its treatment were introduced in the market more than forty years ago and worsen is that they have low efficacy and cause various severe side effects. <br />Although the current clinical scenario is of course discouraging and is far from being even a soothing treatment for those who suffer from the disease, it prompt ones to set efforts towards the need of discovering and developing new efficacious and safe drugs to treat Chagas disease. <br />Our research group covers the concept of enzymes acting as targets for the action of drugs. Once T. cruzi has many druggable targets, the dihydroorotate dehydrogenase enzyme (TcDHODH) that belongs to the de novo pyrimidine nucleotide synthetic pathway has been chosen for the search of new inhibitors that may be of use in the treatment of Chagas disease. To accomplish with this and considering that inhibitors are molecules that decrease enzyme activity leading to parasite death, we used the concepts and tools of modern computational medicinal chemistry such as in silico screening of small molecules that bind to the active site of the TcDHODH. <br />After a thoroughly program of virtually screening thousands of compounds, 26 were purchased from commercially available sources and experimentally assayed against the TcDHODH using Isothermal Titration Calorimetry (ITC) in order to determine the mechanism of inhibition and the kinetic affinity constant (Kiapp). <br />The first series of inhibitors selected from our in silico strategy were evaluated by ITC to yield compounds that inhibited the TcDHODH in the micromolar concentration range with an average of 0.50 kcal mol-1 atom-1 ligand efficiency (LE). Because the assayed compounds have low molecular weight (ca. 200 kDa) and high LE, which bring them to the specific bimolecular pattern recognition all of them were considered good inhibitors capable of being selected to enter the hit-to-lead optimization process. <br />The detailed description of the ligand-enzyme mode of binding (MOB) is thoroughly accomplished by solving the X ray crystal structure of the surrogate Leishmania major DHODH enzyme (LmDHODH), which has a high degree of similarity with the enzyme TcDHODH. The MOB credited to be in the active site of the TcDHODH orthogonally validated the ITC kinetic experimental data obtained for all ligands as competitive inhibitors that interact at the active site of the TcDHODH and helped to generate pharmacophoric hypotheses for the search of new second generation molecules acting against the enzyme TcDHODH.  Analyzing the 3D structure of the TcDHODH along with its surrogate LmDHODH, we envisaged the possibility of compounds to extend their side chain beyond the region of the catalytic site (called S1), and interacting in a region called S2, so to increase binding affinity. Moreover, the TcDHODH S2 site that is not found in the 3D protein structure of humans (HsDHODH) is likely to offer new insights for the search of inhibitors whose binding to this S2 site can pave the roads towards the needed structural basis for selective inhibition of TcDHODH. <br />The most potent compounds inhibited the enzyme competitively with respect to the substrate dihydroorotate (DHO) at Kiapp values of 121 &plusmn; 14 nM and 190 &plusmn; 10 nM, which constitutes high affinity TcDHODH inhibitors. The ITC technique was pivotal to this process of enzyme inhibitors discovery, because it proved to be extremely sensitive thus allowing to monitor the kinetics of the reaction and to obtain precise and accurate values of affinity constants. <br />The hit rate obtained in this work, considering only those compounds with Kiapp < 100 &micro;M, was 46%. This is a really high number, since literature values range from 1 to 10% when the planning new inhibitors via in silico methods when compared to the success rates obtained by the methods of testing on large scales (HTS), 0-2 %, the results achieved in this work are even more significant. Moreover, the compounds selected through the integration of in silico and calorimetric methods showed a high degree of complexity in the process of bimolecular enzyme-ligand recognition, which allows to pass them to the next phase of the drug design process.